查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1614259

伊文氏肉瘤治療藥物市場：按治療、階段、適應症、最終用戶、分銷管道 - 2025-2030 年全球預測

Ewing Sarcoma Therapeutics Market by Treatment (Chemotherapy, Radiation Therapy, Surgery), Stage of Disease (Localized Ewing Sarcoma, Metastatic Ewing Sarcoma), Indication, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

伊文氏肉瘤治療市場2023年估值為10.1億美元，預計到2024年將達到10.8億美元，複合年成長率為6.83%，預計到2030年將達到16.1億美元。

伊文氏肉瘤治療描述了針對伊文氏肉瘤的治療方法的開發和商業化。伊文氏肉瘤是一種罕見的骨骼和軟組織癌症，主要影響青少年和年輕人。這些治療的需求源於伊文氏肉瘤的侵襲性，以及由於其複雜的病理生理學、復發和抗藥性問題而迫切需要解決未滿足的醫療需求。應用主要集中在化療藥物、標靶治療以及基因治療和免疫治療等新治療方法。最終用途包括醫院、腫瘤中心和專科診所。目前，該市場的促進因素包括發病率上升、精準醫療的進步以及能夠實現早期檢測的診斷技術的改進。新的發展機會在於將人工智慧納入個人化治療計劃和藥物再利用策略，並考慮小型患者群體開發新藥的挑戰。生技公司、研究機構和製藥公司之間的合作可以增加資源共用，降低研發成本和上市時間。然而，挑戰仍然存在，例如臨床試驗的高成本、嚴格的監管要求以及可研究的患者群體有限，阻礙了更廣泛的市場成長。智慧財產權障礙和潛在的倫理問題構成了進一步的限制，特別是對於基因治療應用而言。創新領域包括開發用於早期檢測和預後的生物標記、克服抗藥性的聯合治療以及使用 CRISPR 技術進行標靶基因編輯。因此，確保策略夥伴關係並創造有利於診斷和治療方法創新的環境可以增強競爭優勢並改善治療結果。對研發的持續投資以及監管合規的優先考慮應繼續在克服現有市場挑戰和確保該專業的持續成長方面發揮核心作用。

主要市場統計
基準年[2023] 10.1億美元
預計年份 [2024] 10.8億美元
預測年份 [2030] 16.1億美元
複合年成長率（%） 6.83%

市場動態：揭示快速發展的伊文氏肉瘤藥物市場的關鍵市場洞察

伊文氏肉瘤藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球伊文氏肉瘤盛行率不斷上升
    • 加強對伊文氏肉瘤的認知計畫和教育
  • 市場限制因素
    • 伊文氏肉瘤的治療費用上漲
  • 市場機會
    • 活性化研發力度，引進伊文氏肉瘤的治療方法
    • 伊文氏肉瘤標靶治療的潛力不斷增加
  • 市場挑戰
    • 伊文氏肉瘤特異性藥物開發與製造的複雜性

波特的五力：駕馭伊文氏肉瘤藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解伊文氏肉瘤藥物市場的外部影響

外部宏觀環境因素在塑造伊文氏肉瘤治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解伊文氏肉瘤治療藥物市場的競爭狀況

伊文氏肉瘤治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣伊文氏肉瘤治療市場供應商的績效評估

FPNV 定位矩陣是評估伊文氏肉瘤治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為尤文氏伊文氏肉瘤藥物市場的成功指明道路

對伊文氏肉瘤藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球伊文氏肉瘤發生率增加
      • 加強對伊文氏肉瘤的認知計畫和教育
    • 抑制因素
      • 伊文氏肉瘤的治療費用很高。
    • 機會
      • 擴大研究和開發力度，引入伊文氏肉瘤的有效治療方法
      • 伊文氏肉瘤標靶治療的潛力增加
    • 任務
      • 伊文氏肉瘤特定藥物開發與製造的複雜性
  • 市場區隔分析
    • 治療：越來越需要放射線治療來消滅癌細胞
    • 最終用戶：透過醫院和診所更多地獲得伊文氏肉瘤藥物
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章伊文氏肉瘤藥物市場（依治療）

  • 化療
  • 放射治療
  • 外科手術
  • 標靶治療

第7章依疾病階段伊文氏肉瘤治療藥物市場

  • 局部伊文氏肉瘤
  • 轉移性伊文氏肉瘤

第8章伊文氏肉瘤治療藥物市場（按適應症）

  • 阿斯金瘤
  • 骨腫瘤
  • 周邊原始神經外胚層腫瘤
  • 軟組織腫瘤

第9章伊文氏肉瘤治療藥物市場：依最終用戶分類

  • 癌症治療中心
  • 醫院/診所

第10章伊文氏肉瘤治療藥物市場：按分銷管道

  • 醫院藥房
  • 網路藥房

第11章美洲伊文氏肉瘤治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區伊文氏肉瘤治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲伊文氏肉瘤治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Inhiflex 報告治療伊文氏肉瘤的第一期研究結果取得進展
    • 住友製藥腫瘤公司的 TP-1287 獲得治療伊文氏肉瘤的孤兒藥資格
    • 奈米醫學在伊文氏肉瘤個人化治療方面取得突破
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson and Johnson, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sumitomo Pharma Oncology, Inc.
Product Code: MRR-CB04E05652A3

The Ewing Sarcoma Therapeutics Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.08 billion in 2024, and is projected to grow at a CAGR of 6.83%, to USD 1.61 billion by 2030.

Ewing Sarcoma Therapeutics involves the development and commercialization of treatments specifically targeting Ewing Sarcoma, a rare form of cancer typically occurring in bones or soft tissue, affecting predominantly adolescents and young adults. The necessity of these therapeutics stems from the aggressive nature of Ewing Sarcoma and the urgency to address unmet medical needs due to its complex pathophysiology, recurrence, and resistance issues. Applications primarily focus on chemotherapeutic agents, targeted therapies, and emerging modalities like gene therapy and immunotherapy. End-use extends across hospitals, oncology centers, and specialized clinics. The market is currently driven by increasing incidence rates, advancements in precision medicine, and better diagnostic techniques enabling early detection. Emerging opportunities lie in the incorporation of Artificial Intelligence for personalized treatment plans and in drug repurposing strategies, given the challenges of developing new drugs for a small patient cohort. Collaborations between biotech firms, research institutes, and pharmaceutical companies could facilitate sharing of resources, thereby reducing R&D costs and time-to-market. However, challenges persist, including high costs of clinical trials, stringent regulatory requirements, and limited patient populations for testing, which hinder broader market growth. Intellectual Property obstacles and potential ethical concerns, particularly with gene therapy applications, present further limitations. Innovative areas may include the development of biomarkers for early detection and prognosis, combination therapies to overcome resistance, and leveraging CRISPR technologies for targeted gene editing. The Ewing Sarcoma Therapeutics market is predominantly research-driven with a niche focus; hence, ensuring strategic partnerships and fostering an environment conducive to innovation in diagnostics and treatment methodologies could bolster competitive advantage, potentially leading to enhanced therapeutic outcomes. Continuous investment in R&D and prioritizing regulatory compliance should remain central to overcoming existing market challenges and ensuring sustainable growth in this specialized field.

KEY MARKET STATISTICS
Base Year [2023] USD 1.01 billion
Estimated Year [2024] USD 1.08 billion
Forecast Year [2030] USD 1.61 billion
CAGR (%) 6.83%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ewing Sarcoma Therapeutics Market

The Ewing Sarcoma Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of Ewing Sarcoma worldwide
    • Increasing awareness programs and education about Ewing sarcoma
  • Market Restraints
    • High cost of Ewing sarcoma treatments
  • Market Opportunities
    • Growing research & development activities to introduce effective Ewing sarcoma treatments
    • Increasing potential for targeted therapy for Ewing sarcoma
  • Market Challenges
    • Complexities in drug development and manufacturing specific to Ewing sarcoma

Porter's Five Forces: A Strategic Tool for Navigating the Ewing Sarcoma Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ewing Sarcoma Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ewing Sarcoma Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ewing Sarcoma Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ewing Sarcoma Therapeutics Market

A detailed market share analysis in the Ewing Sarcoma Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ewing Sarcoma Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ewing Sarcoma Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ewing Sarcoma Therapeutics Market

A strategic analysis of the Ewing Sarcoma Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ewing Sarcoma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., Amneal Pharmaceuticals Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson and Johnson, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., and Sumitomo Pharma Oncology, Inc..

Market Segmentation & Coverage

This research report categorizes the Ewing Sarcoma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Chemotherapy, Radiation Therapy, Surgery, and Targeted Therapy.
  • Based on Stage of Disease, market is studied across Localized Ewing Sarcoma and Metastatic Ewing Sarcoma.
  • Based on Indication, market is studied across Askin Tumor, Bone Tumor, Peripheral Primitive Neuroectodermal Tumor, and Soft Tissue Tumor.
  • Based on End-User, market is studied across Cancer Treatment Centers and Hospitals & Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies and Online Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of Ewing Sarcoma worldwide
      • 5.1.1.2. Increasing awareness programs and education about Ewing sarcoma
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of Ewing sarcoma treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research & development activities to introduce effective Ewing sarcoma treatments
      • 5.1.3.2. Increasing potential for targeted therapy for Ewing sarcoma
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in drug development and manufacturing specific to Ewing sarcoma
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Growing need for radiation therapy to destroy cancer cells
    • 5.2.2. End-User: High accessibility of Ewing sarcoma therapeutics through hospitals & clinics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Ewing Sarcoma Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Radiation Therapy
  • 6.4. Surgery
  • 6.5. Targeted Therapy

7. Ewing Sarcoma Therapeutics Market, by Stage of Disease

  • 7.1. Introduction
  • 7.2. Localized Ewing Sarcoma
  • 7.3. Metastatic Ewing Sarcoma

8. Ewing Sarcoma Therapeutics Market, by Indication

  • 8.1. Introduction
  • 8.2. Askin Tumor
  • 8.3. Bone Tumor
  • 8.4. Peripheral Primitive Neuroectodermal Tumor
  • 8.5. Soft Tissue Tumor

9. Ewing Sarcoma Therapeutics Market, by End-User

  • 9.1. Introduction
  • 9.2. Cancer Treatment Centers
  • 9.3. Hospitals & Clinics

10. Ewing Sarcoma Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies

11. Americas Ewing Sarcoma Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Ewing Sarcoma Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Ewing Sarcoma Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Inhibrx Reports Progress in Ewing Sarcoma Treatment with Phase 1 Trial Results
    • 14.3.2. Orphan Drug Designation Awarded to Sumitomo Pharma Oncology's TP-1287 for Ewing Sarcoma Treatment
    • 14.3.3. Breakthrough in Personalized Treatment for Ewing Sarcoma Using Nanomedicine
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amgen Inc.
  • 3. Amneal Pharmaceuticals Inc.
  • 4. AstraZeneca plc
  • 5. Bayer AG
  • 6. Bristol-Myers Squibb Company
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. GlaxoSmithKline PLC
  • 10. Johnson and Johnson, Inc.
  • 11. Merck KGaA
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Sumitomo Pharma Oncology, Inc.

LIST OF FIGURES

  • FIGURE 1. EWING SARCOMA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. EWING SARCOMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EWING SARCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. EWING SARCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. EWING SARCOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. EWING SARCOMA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY LOCALIZED EWING SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY METASTATIC EWING SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY ASKIN TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY BONE TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY SOFT TISSUE TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM EWING SARCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. EWING SARCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. EWING SARCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023